Table 2. Comparison of characteristics after 3 months of biological disease-modifying antirheumatic drug (bDMARD) therapy between the patients with high and low anti-Porphyromonas gingivalis peptidylarginine deiminase (PPAD) immunoglobulin G (IgG) titers.
| Parameter | High titer group a (N = 30) | Low titer group a (N = 30) | P-value |
|---|---|---|---|
| Periodontal | |||
| Teeth present, no. (SD) | 24.6 (4.7) | 25.4 (3.5) | 0.52 |
| Plaque control record, mean (SD) % | 33.4 (19.7) | 32.0 (20.9) | 0.67 |
| Gingival index, mean (SD) | 0.8 (0.2) | 0.9 (0.2) | 0.26 |
| Bleeding on probing, mean (SD) % | 6.6 (9.4) | 5.3 (8.0) | 0.61 |
| Probing depth, mean (SD) mm | 2.5 (0.3) | 2.5 (0.3) | 0.99 |
| Clinical attachment level, mean (SD) mm | 2.7 (0.5) | 2.7 (0.4) | 0.95 |
| Rheumatologic | |||
| DAS28-CRP, mean (SD) | 2.9 (1.1) | 2.2 (0.7) | 0.02* |
| Tender joint count, mean (SD) | 3.0 (3.7) | 1.3 (1.4) | 0.07 |
| Swollen joint count, mean (SD) | 2.9 (3.7) | 1.4 (2.0) | 0.10 |
| VAS, mean (SD) mm | 28.9 (19.6) | 20.4 (18.3) | 0.06 |
| Anti-CCP IgG level, mean (SD) U/mL | 126.2 (166.8) | 111.0 (126.7) | 0.57 |
| RF level, mean (SD) IU/mL | 155.8 (375.9) | 79.0 (122.9) | 0.41 |
| CRP level, mean (SD) mg/dL | 0.8 (1.5) | 0.1 (0.2) | 0.05 |
SD: standard deviation; DAS28-CRP: disease activity score including 28 joints using C-reactive protein; VAS: visual analog scale; CCP: cyclic citrullinated peptide; RF: rheumatoid factor.
a Anti-PPAD IgG cut-off level, 0.822 ELISA unit.
* Significantly different between the groups (P < 0.05) (bold value).